May 22, 2023

Tryp Therapeutics discusses unique approach to psychedelic treatment study of binge eating

Welcome aboard! Your submission has been received and you are now a member of the community.
Oops! Something went wrong while submitting the form. Please check the format of your entry.
Subscribe to Excellence

Tryp Therapeutics (CSE:TRYP, OTC:TRYPF) CEO James Gilligan joins Natalie Stoberman from the Proactive studio to share how the company is developing psychedelic-assisted therapy in treating various disorders such as binge eating and IBS.

Gilligan says Tryp Therapeutics is taking a unique approach with their product, TRP-8803, which is an IV infusion of psilocin, an active metabolite of psilocybin. Currently, Gilligan says the company is using oral psilocybin in their studies while preparing for the use of TRP-8803. Tryp Therapeutics recently secured a $2.4 million private placement that Gilligan says will allow the company to continue their research and upcoming clinical trials.

Contact Details

Proactive Investors

+1 604-688-8158

Copyright (c) 2023 TheNewswire - All rights reserved.


The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on for important risk disclosures. It’s your money and your responsibility.

Other News

See All News

Other Articles

See All Articles